Patients Suffering Both Stevens-Johnson Syndrome and Liver Damage Face Higher Death Risk: Study

The findings of a new study shows that when medications cause both a Stevens-Johnson syndrome skin reaction and liver damage, patients have lowered chances of survival. 

In a study published recently in the medical journal Hepatology, researchers from Bangalore, India found that more than a third of patients died when a drug reaction caused them to suffer both drug-induced liver injury (DILI) and either Stevens-Johnson syndrome (SJS) or the more dangerous version of SJS, toxic epidermal necrosis (TEN).

Stevens-Johnson Syndrome is a serious reaction that has been linked to a number of different medications, which involves the burning of the skin from the inside out, producing blisters, severe rash and often causing the skin to separate from the body. It also often results in vision loss or blindness.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

When the skin lesions affect more than 30% of the body, the condition is typically referred to as toxic epidermal necrolysis (TEN). Treatment in a hospital Intensive Care Unit (ICU) or Burn Unit is often required, and the conditions can be fatal in many cases.

The researchers collected data on 36 cases of Stevens-Johnson Syndrome or toxic epidermal necrosis among patients at a single clinical center in India from 1997 to 2015. Most of the cases were linked to what are considered “high risk” drugs, such as antiepileptic agents, sulfonamides, and antiretroviral drugs.

The study found that 36% of patients who suffered both liver problems and skin reactions died as a result. Those who suffered jaundice as a result of the liver problems had a 45.5% mortality rate. However, children and those with HIV suffered significantly lower death rates; 11% and 12.5%, respectively.

“DILI associated with SJS/TEN is rare and associated with a high death rate, particularly in those with jaundice; however, children and human immunodeficiency virus-infected individuals have a favorable outcome,” the researchers noted. “[A] small group of drugs contributed to a disproportioate number of cases, and causality….was highly probable in all cases.”

Image Credit: |

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.